Sökresultat
Novartis analys bekräftar nyttan av Kymriah® på patienter med vissa typer av lymfom
…estricted T-cell response. These results are consistent with historical outcomes for patients with Myc- and Myc+ expression4. Analyses to further identify biomarkers for response to CAR-T cell therapy are ongoing. More information about Novartis activities at ASH can be found on the Novartis 2020 ASH Annual Meeting virtual portal. About the ELARA trial ELARA is a Phase II, single-arm, multicenter, open-label trial investigating the efficacy and sa…
Längre progressionsfri överlevnad för patienter med HER2-positiv spridd bröstcancer som behandlats med Enhertu (trastuzumab deruxtecan)
…kyo and AstraZeneca entered into a global collaboration to jointly develop and commercialise Enhertu (a HER2-directed ADC) in March 2019, and datopotamab deruxtecan (DS-1062; a TROP2-directed ADC) in July 2020, except in Japan where Daiichi Sankyo maintains exclusive rights. Daiichi Sankyo is responsible for manufacturing and supply of Enhertu and datopotamab deruxtecan. AstraZeneca in breast cancer Driven by a growing understanding of breast canc…
Novartis får positiv rekommendation för godkännande av CHMP för Scemblix®
…incidence ≥ 20%) adverse reactions reported in this analysis were thrombocytopenia (29.5%) and neutropenia (23.1%) in the Scemblix arm; and diarrhea (71.1%), nausea (46.1%), increased ALT (28.9%), vomiting (26.3%), rash (23.7%), increased AST (21.1%) and neutropenia (21.1%) in the Bosulif arm1. These results were confirmed in longer-term follow-up, where the MMR rate at week 96 was more than double with Scemblix (37.6%, 95% CI: 29.99-45.65) comp…
Tagrisso-studie avblindas i förtid baserat på överväldigande effekt
…GFR-mutated lung cancer ADAURA is the first global trial for an EGFR inhibitor to show statistically significant and clinically meaningful benefit in adjuvant treatment of lung cancer Plans for regulatory submission already underway The ADAURA Phase III trial for Tagrisso (osimertinib) in the adjuvant treatment of patients with Stage IB, II and IIIA epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) with complete t…
Calquence minskade risken för sjukdomsprogress eller död med 71% efter 3 år
…d in an exploratory analysis comparing each regimen with Calquence. Safety and tolerability of Calquence were consistent with earlier findings, with no new safety signals identified.1 Additional safety analyses from the ELEVATE-RR Phase III trial were also presented at ASH to further characterise adverse events (AEs) related to treatment with Bruton’s tyrosine kinase (BTK) inhibitors Calquence and ibrutinib. Overall, patients on ibrutinib experien…